Advertisement

Journal of Neuro-Oncology

, Volume 133, Issue 1, pp 183–192 | Cite as

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis

  • Timothy E. Richardson
  • Matija Snuderl
  • Jonathan Serrano
  • Matthias A. Karajannis
  • Adriana Heguy
  • Dwight Oliver
  • Jack M. Raisanen
  • Elizabeth A. Maher
  • Edward Pan
  • Samuel Barnett
  • Chunyu Cai
  • Amyn A. Habib
  • Robert M. Bachoo
  • Kimmo J. HatanpaaEmail author
Clinical Study

Abstract

According to the recently updated World Health Organization (WHO) classification (2016), grade II–III astrocytomas are divided into IDH-wildtype and IDH-mutant groups, the latter being significantly less aggressive in terms of both progression-free and total survival. We identified a small cohort of WHO grade II–III astrocytomas that harbored the IDH1 R132H mutation, as confirmed by both immunohistochemistry and molecular sequence analysis, which nonetheless had unexpectedly rapid recurrence and subsequent progression to glioblastoma. Among these four cases, the mean time to recurrence as glioblastoma was only 16 months and the mean total survival among the three patients who have died during the follow-up was only 31 months. We hypothesized that these tumors had other, unfavorable genetic or epigenetic alterations that negated the favorable effect of the IDH mutation. We applied genome-wide profiling with a methylation array (Illumina Infinium Human Methylation 450k) to screen for genetic and epigenetic alterations in these tumors. As expected, the methylation profiles of all four tumors were found to match most closely with IDH-mutant astrocytomas. Compared with a control group of four indolent, age-similar WHO grade II–III astrocytomas, the tumors showed markedly increased levels of overall copy number changes, but no consistent specific genetic alterations were seen across all of the tumors. While most IDH-mutant WHO grade II–III astrocytomas are relatively indolent, a subset may rapidly recur and progress to glioblastoma. The precise underlying cause of the increased aggressiveness in these gliomas remains unknown, although it may be associated with increased genomic instability.

Keywords

Astrocytoma Glioblastoma Rapidly progressing astrocytoma IDH mutation Methylation array 

Notes

Acknowledgements

The authors would like to thank Niccole Williams and Agatha Villegas for administrative professional services. We also thank Ping Shang for some of the immunohistochemical stains. The authors would like to thank Stefan Pfister, David T. W. Jones, Martin Sill and Volker Hovestadt for their help with optimization of the 450 k Illumina Infinium methylation profiling for copy number analysis. A.A.H. was supported, in part, by a grant from the Department of Veteran’s Affairs (I01BX002559). The study was supported by the Friedberg Charitable Foundation grant to M.S. and M.A.K.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

11060_2017_2431_MOESM1_ESM.jpg (828 kb)
Supplemental Figure 1. Copy number analysis derived from the Illumina Infinium Human Methylation 450k array data, showing four conventional, indolent IDH-mutated astrocytomas with no subsequent progression. These four tumors show relatively little copy number changes across all chromosomes compared with the four tumors in our study group. (JPG 827 KB)

References

  1. 1.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14(Suppl 5):v1–v49CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRefPubMedGoogle Scholar
  3. 3.
    Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hartmann C, Meyer J, Balss J, Capper D, Mueller W et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474CrossRefPubMedGoogle Scholar
  5. 5.
    Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRefPubMedGoogle Scholar
  7. 7.
    Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437CrossRefPubMedGoogle Scholar
  8. 8.
    Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V et al (2014) Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128:561–571CrossRefPubMedGoogle Scholar
  9. 9.
    Orillac C, Thomas C, Dastagirzada Y, Hidalgo ET, Golfinos JG et al (2016) Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation. Acta Neuropathol Commun 4:84CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N et al (2017) Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 133:417–429CrossRefPubMedGoogle Scholar
  11. 11.
    Hatanpaa KJ, Hu T, Vemireddy V, Foong C, Raisanen JM et al (2014) High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II–III astrocytomas and oligoastrocytomas. J Neurooncol 117:183–189CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH et al (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810–817CrossRefPubMedGoogle Scholar
  13. 13.
    Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y et al (2015) Revisiting TP53 mutations and Immunohistochemistry—a comparative study in 157 diffuse gliomas. Brain Pathol 25:256–265CrossRefPubMedGoogle Scholar
  14. 14.
    Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L et al (2009) Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 1:177–200CrossRefPubMedGoogle Scholar
  15. 15.
    Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116CrossRefPubMedGoogle Scholar
  16. 16.
    Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B et al (2011) High density DNA methylation array with single CpG site resolution. Genomics 98:288–295CrossRefPubMedGoogle Scholar
  17. 17.
    Feinberg AP (2010) Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat Biotechnol 28:1049–1052CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Feinberg AP (2010) Genome-scale approaches to the epigenetics of common human disease. Virchows Arch 456:13–21CrossRefPubMedGoogle Scholar
  19. 19.
    Petronis A (2010) Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 465:721–727CrossRefPubMedGoogle Scholar
  20. 20.
    Rakyan VK, Down TA, Balding DJ, Beck S (2011) Epigenome-wide association studies for common human diseases. Nat Rev Genet 12:529–541CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D et al (2014) Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 20:2898–2909CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Finver SN, Nishikura K, Finger LR, Haluska FG, Finan J et al (1988) Sequence analysis of the MYC oncogene involved in the t(8;14)(q24;q11) chromosome translocation in a human leukemia T-cell line indicates that putative regulatory regions are not altered. Proc Natl Acad Sci USA 85:3052–3056CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nilsson JA, Cleveland JL (2003) Myc pathways provoking cell suicide and cancer. Oncogene 22:9007–9021CrossRefPubMedGoogle Scholar
  24. 24.
    Sheiness D, Bister K, Moscovici C, Fanshier L, Gonda T et al (1980) Avian retroviruses that cause carcinoma and leukemia: identification of nucleotide sequences associated with pathogenicity. J Virol 33:962–968PubMedPubMedCentralGoogle Scholar
  25. 25.
    Cotterman R, Knoepfler PS (2009) N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b. PLoS ONE 4:e5799CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A et al (2008) N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 68:9654–9662CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Bai H, Harmanci AS, Erson-Omay EZ, Li J, Coskun S et al (2016) Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet 48:59–66CrossRefPubMedGoogle Scholar
  28. 28.
    Tateishi K, Iafrate AJ, Ho Q, Curry WT, Batchelor TT et al (2016) Myc-driven glycolysis is a therapeutic target in glioblastoma. Clin Cancer Res 22:4452–4465CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24:2899–2908CrossRefPubMedGoogle Scholar
  30. 30.
    Haupt Y, Barak Y, Oren M (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 15:1596–1606PubMedPubMedCentralGoogle Scholar
  31. 31.
    Haupt Y, Oren M (1996) p53-mediated apoptosis: mechanisms and regulation. Behring Inst Mitt 97:32–59Google Scholar
  32. 32.
    England B, Huang T, Karsy M (2013) Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 34:2063–2074CrossRefPubMedGoogle Scholar
  33. 33.
    Biernat W, Kleihues P, Yonekawa Y, Ohgaki H (1997) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56:180–185CrossRefPubMedGoogle Scholar
  34. 34.
    Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235–2241CrossRefPubMedGoogle Scholar
  35. 35.
    Lukashchuk N, Vousden KH (2007) Ubiquitination and degradation of mutant p53. Mol Cell Biol 27:8284–8295CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD et al (1993) p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231–2234PubMedGoogle Scholar
  37. 37.
    Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245CrossRefPubMedGoogle Scholar
  38. 38.
    Oliner JD (1993) Discerning the function of p53 by examining its molecular interactions. Bioessays 15:703–707CrossRefPubMedGoogle Scholar
  39. 39.
    Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW et al (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857–860CrossRefPubMedGoogle Scholar
  40. 40.
    Olson DC, Marechal V, Momand J, Chen J, Romocki C et al (1993) Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8:2353–2360PubMedGoogle Scholar
  41. 41.
    Rayburn E, Zhang R, He J, Wang H (2005) MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27–41CrossRefPubMedGoogle Scholar
  42. 42.
    Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S et al (2013) Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS ONE 8:e72281CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223–241CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848CrossRefPubMedGoogle Scholar
  45. 45.
    Vu BT, Vassilev L (2011) Small-molecule inhibitors of the p53-MDM2 interaction. Curr Top Microbiol Immunol 348:151–172PubMedGoogle Scholar
  46. 46.
    Yu S, Qin D, Shangary S, Chen J, Wang G et al (2009) Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 52:7970–7973CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K et al (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159–168CrossRefPubMedGoogle Scholar
  48. 48.
    Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H (1997) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 94:303–309CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Timothy E. Richardson
    • 1
  • Matija Snuderl
    • 2
  • Jonathan Serrano
    • 2
  • Matthias A. Karajannis
    • 2
  • Adriana Heguy
    • 2
  • Dwight Oliver
    • 1
  • Jack M. Raisanen
    • 1
  • Elizabeth A. Maher
    • 3
    • 4
  • Edward Pan
    • 4
    • 5
  • Samuel Barnett
    • 5
  • Chunyu Cai
    • 1
  • Amyn A. Habib
    • 4
    • 6
  • Robert M. Bachoo
    • 4
  • Kimmo J. Hatanpaa
    • 1
    Email author
  1. 1.Department of PathologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Department of PathologyNew York University Langone Medical CenterNew York CityUSA
  3. 3.Department of Internal MedicineUniversity of Texas Southwestern Medical CenterDallasUSA
  4. 4.Department of Neurology and NeurotherapeuticsUniversity of Texas Southwestern Medical CenterDallasUSA
  5. 5.Department of Neurological SurgeryUniversity of Texas Southwestern Medical CenterDallasUSA
  6. 6.North Texas Veterans Affairs Medical CenterDallasUSA

Personalised recommendations